PMC:7195088 / 26137-29724 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T26","span":{"begin":2932,"end":2938},"obj":"Body_part"},{"id":"T27","span":{"begin":3198,"end":3201},"obj":"Body_part"},{"id":"T28","span":{"begin":3260,"end":3263},"obj":"Body_part"}],"attributes":[{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62872"}],"text":"• Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).\n• Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not yet recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.\n• Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. Double-blind RCT (NCT04308668, recruiting). Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not yet recruiting). Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).\n• Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not yet recruiting). Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T20","span":{"begin":2389,"end":2394},"obj":"Body_part"},{"id":"T21","span":{"begin":2876,"end":2881},"obj":"Body_part"},{"id":"T22","span":{"begin":3571,"end":3576},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"uberon_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"• Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).\n• Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not yet recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.\n• Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. Double-blind RCT (NCT04308668, recruiting). Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not yet recruiting). Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).\n• Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not yet recruiting). Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T129","span":{"begin":408,"end":416},"obj":"Disease"},{"id":"T130","span":{"begin":527,"end":535},"obj":"Disease"},{"id":"T131","span":{"begin":637,"end":645},"obj":"Disease"},{"id":"T132","span":{"begin":794,"end":802},"obj":"Disease"},{"id":"T133","span":{"begin":1072,"end":1080},"obj":"Disease"},{"id":"T134","span":{"begin":1150,"end":1158},"obj":"Disease"},{"id":"T135","span":{"begin":1270,"end":1278},"obj":"Disease"},{"id":"T136","span":{"begin":1426,"end":1434},"obj":"Disease"},{"id":"T137","span":{"begin":1475,"end":1483},"obj":"Disease"},{"id":"T138","span":{"begin":1665,"end":1673},"obj":"Disease"},{"id":"T139","span":{"begin":1789,"end":1797},"obj":"Disease"},{"id":"T140","span":{"begin":1923,"end":1931},"obj":"Disease"},{"id":"T141","span":{"begin":2047,"end":2055},"obj":"Disease"},{"id":"T142","span":{"begin":2058,"end":2067},"obj":"Disease"},{"id":"T143","span":{"begin":2154,"end":2162},"obj":"Disease"},{"id":"T144","span":{"begin":2306,"end":2314},"obj":"Disease"},{"id":"T145","span":{"begin":2512,"end":2520},"obj":"Disease"},{"id":"T146","span":{"begin":2754,"end":2762},"obj":"Disease"},{"id":"T147","span":{"begin":2850,"end":2858},"obj":"Disease"},{"id":"T148","span":{"begin":3052,"end":3060},"obj":"Disease"},{"id":"T149","span":{"begin":3202,"end":3210},"obj":"Disease"},{"id":"T150","span":{"begin":3452,"end":3460},"obj":"Disease"}],"attributes":[{"id":"A129","pred":"mondo_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A130","pred":"mondo_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A131","pred":"mondo_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A132","pred":"mondo_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A133","pred":"mondo_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A134","pred":"mondo_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A135","pred":"mondo_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A136","pred":"mondo_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A146","pred":"mondo_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A147","pred":"mondo_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A148","pred":"mondo_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A149","pred":"mondo_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"• Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).\n• Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not yet recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.\n• Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. Double-blind RCT (NCT04308668, recruiting). Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not yet recruiting). Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).\n• Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not yet recruiting). Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T136","span":{"begin":127,"end":128},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T137","span":{"begin":201,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T138","span":{"begin":281,"end":282},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T139","span":{"begin":343,"end":344},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T140","span":{"begin":809,"end":814},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T141","span":{"begin":874,"end":875},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T142","span":{"begin":921,"end":922},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T143","span":{"begin":1087,"end":1092},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T144","span":{"begin":1183,"end":1188},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T145","span":{"begin":1405,"end":1406},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T146","span":{"begin":1446,"end":1448},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T147","span":{"begin":1458,"end":1459},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T148","span":{"begin":1495,"end":1497},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T149","span":{"begin":1540,"end":1542},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T150","span":{"begin":1585,"end":1587},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T151","span":{"begin":2017,"end":2018},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T152","span":{"begin":2278,"end":2279},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T153","span":{"begin":2349,"end":2350},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T154","span":{"begin":2371,"end":2374},"obj":"http://purl.obolibrary.org/obo/CLO_0001577"},{"id":"T155","span":{"begin":2527,"end":2532},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T156","span":{"begin":2932,"end":2938},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T157","span":{"begin":3067,"end":3072},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T158","span":{"begin":3132,"end":3133},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T159","span":{"begin":3145,"end":3150},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T160","span":{"begin":3185,"end":3186},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T161","span":{"begin":3553,"end":3556},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"}],"text":"• Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).\n• Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not yet recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.\n• Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. Double-blind RCT (NCT04308668, recruiting). Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not yet recruiting). Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).\n• Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not yet recruiting). Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T352","span":{"begin":26,"end":44},"obj":"Chemical"},{"id":"T353","span":{"begin":201,"end":206},"obj":"Chemical"},{"id":"T354","span":{"begin":475,"end":493},"obj":"Chemical"},{"id":"T355","span":{"begin":498,"end":511},"obj":"Chemical"},{"id":"T357","span":{"begin":507,"end":511},"obj":"Chemical"},{"id":"T358","span":{"begin":683,"end":694},"obj":"Chemical"},{"id":"T359","span":{"begin":700,"end":718},"obj":"Chemical"},{"id":"T360","span":{"begin":724,"end":736},"obj":"Chemical"},{"id":"T361","span":{"begin":741,"end":752},"obj":"Chemical"},{"id":"T362","span":{"begin":758,"end":776},"obj":"Chemical"},{"id":"T363","span":{"begin":809,"end":814},"obj":"Chemical"},{"id":"T364","span":{"begin":1020,"end":1038},"obj":"Chemical"},{"id":"T365","span":{"begin":1087,"end":1092},"obj":"Chemical"},{"id":"T366","span":{"begin":1222,"end":1240},"obj":"Chemical"},{"id":"T367","span":{"begin":1321,"end":1331},"obj":"Chemical"},{"id":"T368","span":{"begin":1612,"end":1630},"obj":"Chemical"},{"id":"T369","span":{"begin":1858,"end":1877},"obj":"Chemical"},{"id":"T370","span":{"begin":1858,"end":1867},"obj":"Chemical"},{"id":"T371","span":{"begin":1868,"end":1877},"obj":"Chemical"},{"id":"T372","span":{"begin":2108,"end":2126},"obj":"Chemical"},{"id":"T373","span":{"begin":2422,"end":2432},"obj":"Chemical"},{"id":"T374","span":{"begin":2437,"end":2455},"obj":"Chemical"},{"id":"T375","span":{"begin":2460,"end":2470},"obj":"Chemical"},{"id":"T376","span":{"begin":2476,"end":2494},"obj":"Chemical"},{"id":"T377","span":{"begin":2527,"end":2532},"obj":"Chemical"},{"id":"T378","span":{"begin":2668,"end":2687},"obj":"Chemical"},{"id":"T379","span":{"begin":2668,"end":2677},"obj":"Chemical"},{"id":"T380","span":{"begin":2678,"end":2687},"obj":"Chemical"},{"id":"T381","span":{"begin":2692,"end":2710},"obj":"Chemical"},{"id":"T382","span":{"begin":2715,"end":2723},"obj":"Chemical"},{"id":"T383","span":{"begin":2944,"end":2962},"obj":"Chemical"},{"id":"T384","span":{"begin":2968,"end":2980},"obj":"Chemical"},{"id":"T385","span":{"begin":2985,"end":3003},"obj":"Chemical"},{"id":"T386","span":{"begin":3009,"end":3021},"obj":"Chemical"},{"id":"T387","span":{"begin":3067,"end":3072},"obj":"Chemical"},{"id":"T388","span":{"begin":3308,"end":3327},"obj":"Chemical"},{"id":"T389","span":{"begin":3308,"end":3317},"obj":"Chemical"},{"id":"T390","span":{"begin":3318,"end":3327},"obj":"Chemical"},{"id":"T391","span":{"begin":3332,"end":3350},"obj":"Chemical"},{"id":"T392","span":{"begin":3355,"end":3374},"obj":"Chemical"},{"id":"T393","span":{"begin":3355,"end":3364},"obj":"Chemical"},{"id":"T394","span":{"begin":3365,"end":3374},"obj":"Chemical"},{"id":"T395","span":{"begin":3380,"end":3390},"obj":"Chemical"},{"id":"T396","span":{"begin":3391,"end":3395},"obj":"Chemical"},{"id":"T397","span":{"begin":3403,"end":3413},"obj":"Chemical"}],"attributes":[{"id":"A352","pred":"chebi_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A353","pred":"chebi_id","subj":"T353","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A354","pred":"chebi_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A355","pred":"chebi_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/CHEBI_22652"},{"id":"A356","pred":"chebi_id","subj":"T355","obj":"http://purl.obolibrary.org/obo/CHEBI_29073"},{"id":"A357","pred":"chebi_id","subj":"T357","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A358","pred":"chebi_id","subj":"T358","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A359","pred":"chebi_id","subj":"T359","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A360","pred":"chebi_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A361","pred":"chebi_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A362","pred":"chebi_id","subj":"T362","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A363","pred":"chebi_id","subj":"T363","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A364","pred":"chebi_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A365","pred":"chebi_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A366","pred":"chebi_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A367","pred":"chebi_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A368","pred":"chebi_id","subj":"T368","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A369","pred":"chebi_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A370","pred":"chebi_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A371","pred":"chebi_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A372","pred":"chebi_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A373","pred":"chebi_id","subj":"T373","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A374","pred":"chebi_id","subj":"T374","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A375","pred":"chebi_id","subj":"T375","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A376","pred":"chebi_id","subj":"T376","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A377","pred":"chebi_id","subj":"T377","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A378","pred":"chebi_id","subj":"T378","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A379","pred":"chebi_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A380","pred":"chebi_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A381","pred":"chebi_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A382","pred":"chebi_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/CHEBI_6541"},{"id":"A383","pred":"chebi_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A384","pred":"chebi_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A385","pred":"chebi_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A386","pred":"chebi_id","subj":"T386","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A387","pred":"chebi_id","subj":"T387","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A388","pred":"chebi_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A389","pred":"chebi_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A390","pred":"chebi_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A391","pred":"chebi_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A392","pred":"chebi_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A393","pred":"chebi_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A394","pred":"chebi_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A395","pred":"chebi_id","subj":"T395","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A396","pred":"chebi_id","subj":"T396","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A397","pred":"chebi_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"• Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).\n• Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not yet recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.\n• Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. Double-blind RCT (NCT04308668, recruiting). Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not yet recruiting). Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).\n• Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not yet recruiting). Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}

{"project":"LitCovid-sentences","denotations":[{"id":"T194","span":{"begin":136,"end":260},"obj":"Sentence"},{"id":"T195","span":{"begin":261,"end":458},"obj":"Sentence"},{"id":"T196","span":{"begin":459,"end":545},"obj":"Sentence"},{"id":"T197","span":{"begin":546,"end":597},"obj":"Sentence"},{"id":"T198","span":{"begin":598,"end":666},"obj":"Sentence"},{"id":"T199","span":{"begin":667,"end":803},"obj":"Sentence"},{"id":"T200","span":{"begin":804,"end":853},"obj":"Sentence"},{"id":"T201","span":{"begin":854,"end":1081},"obj":"Sentence"},{"id":"T202","span":{"begin":1082,"end":1131},"obj":"Sentence"},{"id":"T203","span":{"begin":1132,"end":1205},"obj":"Sentence"},{"id":"T204","span":{"begin":1206,"end":1332},"obj":"Sentence"},{"id":"T205","span":{"begin":1333,"end":1384},"obj":"Sentence"},{"id":"T206","span":{"begin":1385,"end":1595},"obj":"Sentence"},{"id":"T207","span":{"begin":1596,"end":1704},"obj":"Sentence"},{"id":"T208","span":{"begin":1705,"end":1756},"obj":"Sentence"},{"id":"T209","span":{"begin":1757,"end":1819},"obj":"Sentence"},{"id":"T210","span":{"begin":1820,"end":1932},"obj":"Sentence"},{"id":"T211","span":{"begin":1933,"end":1984},"obj":"Sentence"},{"id":"T212","span":{"begin":1985,"end":2002},"obj":"Sentence"},{"id":"T213","span":{"begin":2003,"end":2091},"obj":"Sentence"},{"id":"T214","span":{"begin":2092,"end":2213},"obj":"Sentence"},{"id":"T215","span":{"begin":2214,"end":2257},"obj":"Sentence"},{"id":"T216","span":{"begin":2258,"end":2405},"obj":"Sentence"},{"id":"T217","span":{"begin":2406,"end":2521},"obj":"Sentence"},{"id":"T218","span":{"begin":2522,"end":2580},"obj":"Sentence"},{"id":"T219","span":{"begin":2581,"end":2651},"obj":"Sentence"},{"id":"T220","span":{"begin":2652,"end":2763},"obj":"Sentence"},{"id":"T221","span":{"begin":2764,"end":2825},"obj":"Sentence"},{"id":"T222","span":{"begin":2826,"end":2902},"obj":"Sentence"},{"id":"T223","span":{"begin":2903,"end":3061},"obj":"Sentence"},{"id":"T224","span":{"begin":3062,"end":3111},"obj":"Sentence"},{"id":"T225","span":{"begin":3112,"end":3291},"obj":"Sentence"},{"id":"T226","span":{"begin":3292,"end":3461},"obj":"Sentence"},{"id":"T227","span":{"begin":3462,"end":3515},"obj":"Sentence"},{"id":"T228","span":{"begin":3516,"end":3587},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Comparison of different hydroxychloroquine dosages vs. placebo in three cohorts (outpatients, inpatients, healthcare workers a risk). Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).\n• Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. Double-blind RCT (NCT04328961, not yet recruiting). Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. Open-label RCT (NCT04330586, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.\n• Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. Double-blind RCT (NCT04330495, not yet recruiting). Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).\n• Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. Double-blind RCT (NCT04328467, not yet recruiting). Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. Double-blind RCT (NCT04308668, recruiting). Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.\n• Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. Open-label adaptive RCT (NCT04321616, not yet recruiting). Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).\n• Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. Open-label RCT (NCT04332835, not yet recruiting). Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15."}